Health Advisory: Make Evusheld Available To Eligible Patients
July 21, 2022

The purpose of this health advisory is to remind clinicians about the availability of Evusheld as pre-exposure prophylaxis (PrEP) for COVID-19 in certain adult and pediatric patients (12 years of age and older weighing at least 40 kg). Providers are encouraged to reach out to all patients eligible for Evusheld to discuss risks and benefits and ensure access to this medication. Evusheld is authorized for persons:

- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2, AND
- Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination, or
- For whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s). Evusheld contains polysorbate 80, which is in the Janssen COVID-19 Vaccine and is structurally similar to polyethylene glycol (PEG), an ingredient in the Pfizer-BioNTech and Moderna COVID-19 vaccines. Clinicians should consider consulting an allergist-immunologist prior to administering Evusheld to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to a COVID-19 vaccine.

The authorized Evusheld initial dose is 300 mg of tixagevimab and 300 mg of cilgavimab administered as two separate consecutive intramuscular (IM) injections. If ongoing protection is needed, a repeat dose of 300 mg of tixagevimab and 300 mg of cilgavimab should be administered every 6 months. Despite a decrease in neutralizing activity with currently circulating variants, pharmacokinetic modeling suggests that sufficient activity against these subvariants may be retained for six months.

Please also visit ACPHD’s Treatment webpage.

For questions regarding the distribution of COVID-19 outpatient therapeutic products within ALCO, please contact Cynthia Frankel, RN, Alameda County Therapeutics Distribution Lead at cynthia.frankel@acgov.org

For clinical questions about COVID-19 therapeutics, please contact Arnie Spanjers, MD, Alameda County Public Health Department at arnie.spanjers@acgov.org